Investigational drug · Phase 2
RE104
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adjustment Disorder, Generalized Anxiety Disorder, Postpartum Depression.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
5
Any phase or sponsor naming "RE104"
First trial start
2024
Jun 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RE104", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adjustment Disorder
- Generalized Anxiety Disorder
- Postpartum Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Anxiety disorders · Postpartum depression · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "RE104" as an intervention, largest first.
- RE104 Safety and Efficacy Study in Generalized Anxiety DisorderPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07489651 · 160 participants (planned) · Start Apr 20, 2026 · Primary completion Jul 2027
Drug: RE104 for Injection; Placebo · For: Generalized Anxiety Disorder
Sites: Birmingham, Alabama; Gilbert, Arizona; Little Rock, Arkansas · 28 sites in all
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
Reunion Neuroscience IncIndustry
NCT06342310 · 84 participants · Start Jun 14, 2024 · Primary completion May 22, 2025
Drug: RE104 for Injection · For: Postpartum Depression
Sites: Birmingham, Alabama; Tucson, Arizona; Santa Monica, California · 38 sites in all
- RE104 Clinical Lactation StudyCompleted
Reunion Neuroscience IncIndustry
NCT06659263 · 14 participants · Start Nov 13, 2024 · Primary completion May 28, 2025
Drug: RE104 for Injection · For: Lactation
Sites: Las Vegas, Nevada
Reunion Neuroscience IncIndustry
NCT07146191 · 8 participants · Start Aug 19, 2025 · Primary completion Oct 2, 2025
Drug: 2-[14C]-RE104 for Injection · For: Healthy Participant Study
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study.
Ludbrook G, Bryson N, Taylor B, et al. · J Clin Psychopharmacol 2025
- RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine.
Bryson N, Alexander R, Asnis-Alibozek A, et al. · ACS Chem Neurosci 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.